Wall Street analysts expect Walgreens Boots Alliance Inc (NASDAQ:WBA) to post sales of $33.67 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Walgreens Boots Alliance’s earnings, with the highest sales estimate coming in at $34.31 billion and the lowest estimate coming in at $31.92 billion. Walgreens Boots Alliance posted sales of $30.74 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.5%. The company is scheduled to announce its next earnings report on Thursday, January 3rd.

According to Zacks, analysts expect that Walgreens Boots Alliance will report full-year sales of $137.97 billion for the current financial year, with estimates ranging from $134.52 billion to $139.81 billion. For the next financial year, analysts anticipate that the company will report sales of $142.44 billion, with estimates ranging from $138.20 billion to $145.99 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Walgreens Boots Alliance.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its earnings results on Thursday, October 11th. The pharmacy operator reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.03. The firm had revenue of $33.44 billion during the quarter, compared to analysts’ expectations of $33.64 billion. Walgreens Boots Alliance had a net margin of 3.82% and a return on equity of 21.75%.

A number of research firms have issued reports on WBA. Robert W. Baird lifted their target price on shares of Walgreens Boots Alliance from $69.00 to $71.00 and gave the company a “neutral” rating in a research note on Friday, October 12th. Jefferies Financial Group cut shares of Walgreens Boots Alliance from a “buy” rating to a “hold” rating and reduced their target price for the company from $85.00 to $65.00 in a research note on Friday, June 29th. Citigroup cut shares of Walgreens Boots Alliance from a “buy” rating to a “neutral” rating and set a $69.00 target price for the company. in a research note on Monday, July 9th. BidaskClub upgraded shares of Walgreens Boots Alliance from a “hold” rating to a “buy” rating in a research note on Wednesday, July 18th. Finally, Loop Capital lifted their target price on shares of Walgreens Boots Alliance to $80.00 and gave the company a “buy” rating in a research note on Friday, June 29th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $78.22.

In other news, Director William C. Foote sold 2,736 shares of the business’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $65.99, for a total value of $180,548.64. Following the completion of the sale, the director now directly owns 10,943 shares in the company, valued at $722,128.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 14.80% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. BlueMountain Capital Management LLC bought a new position in Walgreens Boots Alliance during the second quarter worth $103,000. CSat Investment Advisory L.P. bought a new position in Walgreens Boots Alliance during the second quarter worth $104,000. Squar Milner Financial Services LLC bought a new position in Walgreens Boots Alliance during the second quarter worth $106,000. Kaizen Advisory LLC increased its position in Walgreens Boots Alliance by 128.6% during the second quarter. Kaizen Advisory LLC now owns 1,925 shares of the pharmacy operator’s stock worth $116,000 after acquiring an additional 1,083 shares during the period. Finally, Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in Walgreens Boots Alliance during the third quarter worth $154,000. Institutional investors and hedge funds own 61.96% of the company’s stock.

NASDAQ WBA opened at $77.35 on Monday. The company has a quick ratio of 0.38, a current ratio of 0.82 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $73.42 billion, a price-to-earnings ratio of 12.85, a price-to-earnings-growth ratio of 1.21 and a beta of 1.04. Walgreens Boots Alliance has a 12-month low of $59.07 and a 12-month high of $80.68.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

Read More: Float

Get a free copy of the Zacks research report on Walgreens Boots Alliance (WBA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Walgreens Boots Alliance (NASDAQ:WBA)

Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.